Stockscreener 앱 받기
18.39
1.97%
-0.375
전일 마감가:
$18.77
열려 있는:
$18.64
하루 거래량:
1.56M
Relative Volume:
0.42
시가총액:
$4.03B
수익:
$10.68M
순이익/손실:
$-272.71M
주가수익비율:
-11.75
EPS:
-1.565
순현금흐름:
$-213.38M
1주 성능:
-6.88%
1개월 성능:
-2.28%
6개월 성능:
+79.34%
1년 성능:
+412.53%
1일 변동 폭
$18.03
$18.64
1주일 범위
$18.03
$20.77
52주 변동 폭
$3.57
$21.27
릴레이 테라퓨틱스 Stock (RLAY) Company Profile
명칭
Relay Therapeutics Inc
전화
617-370-8837
주소
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
18.40 | 4.32B | 10.68M | -272.71M | -213.38M | -1.565 |
VRTX
Vertex Pharmaceuticals Inc
|
542.17 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,023.65 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.41 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
204.42 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
릴레이 테라퓨틱스 Stock (RLAY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-12-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-04-17 | 개시 | Wells Fargo | Equal Weight |
| 2024-09-10 | 재개 | Goldman | Buy |
| 2024-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-05-10 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-20 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-04-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | 개시 | Raymond James | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-09-30 | 개시 | Barclays | Equal Weight |
| 2022-09-02 | 개시 | Stifel | Buy |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-07-21 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-08 | 개시 | JMP Securities | Mkt Outperform |
| 2020-11-05 | 개시 | H.C. Wainwright | Buy |
| 2020-08-10 | 개시 | Cowen | Outperform |
| 2020-08-10 | 개시 | Goldman | Buy |
| 2020-08-10 | 개시 | Guggenheim | Buy |
| 2020-08-10 | 개시 | JP Morgan | Neutral |
모두보기
릴레이 테라퓨틱스 주식(RLAY)의 최신 뉴스
What is HC Wainwright's Estimate for RLAY FY2027 Earnings? - MarketBeat
RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $29 - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Relay Therapeutics price target to $29 By Investing.com - Investing.com Canada
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE - MarketBeat
Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified? - Yahoo Finance
Relay Therapeutics (RLAY) Stock May Be Fully Valued After A 7x Run - simplywall.st
Timothy G. Youngquist 2020 Irrevocable Trust Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Handelsbanken Fonder AB Buys New Shares in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Insider Sold Shares Worth $979,886, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics (RLAY) CEO sells 48K shares in plan trade - Stock Titan
Relay Therapeutics (RLAY) CFO sells shares via preset trading plan - Stock Titan
Relay (RLAY) Earnings Metrics: EPS Does Not Reach the Reported Estimate in Latest Trading - Vinanet
Relay Therapeutics stock hits 52-week high at 20.83 USD - Investing.com
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - The Globe and Mail
Alphabet Inc. Makes New Investment in Relay Therapeutics, Inc. $RLAY - MarketBeat
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits
Why Is RLAY Stock Rising Today? - Stocktwits
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Persistent Asset Partners Ltd Makes New $1.32 Million Investment in Relay Therapeutics, Inc. $RLAY - MarketBeat
Elmind Capital, LP's Relay Therapeutics Inc(RLAY) Holding History - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
PERCEPTIVE ADVISORS LLC Expands Relay Therapeutics Inc (RLAY) St - GuruFocus
Relay Therapeutics (RLAY): Commodore Capital group discloses 12M-share, 5.5% position - Stock Titan
J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $31 - Moomoo
RLAY Maintained by JP Morgan -- Price Target Raised to $31.00 - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year - Barchart.com
Relay Therapeutics, Inc. $RLAY Shares Bought by California State Teachers Retirement System - MarketBeat
These Analysts Think Relay Therapeutics, Inc.'s (NASDAQ:RLAY) Sales Are Under Threat - simplywall.st
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know - webull.com
Relay Therapeutics (RLAY) Holds at $19.99 as Biotech Consolidates Between Key Support and ResistanceWyckoff Distribution - vinanet.vn
Relay Therapeutics (RLAY): Perceptive Advisors discloses 6.4% ownership stake - Stock Titan
RLAY Maintained by Citizens -- Price Target Raised to $26 - GuruFocus
Citizens Jmp Increases Relay Therapeutics (NASDAQ:RLAY) Price Target to $26.00 - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Reported And Analysts Have Been Cutting Their Estimates - Moomoo
Citizens raises Relay Therapeutics stock price target on progress By Investing.com - in.investing.com
Citizens raises Relay Therapeutics stock price target on progress - Investing.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
RLAY Maintained by Barclays -- Price Target Raised to $30.00 - GuruFocus
FMR LLC (RLAY) discloses 21.27M-share, 10% holding in Relay Therapeutics - Stock Titan
Relay Therapeutics Inc (RLAY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Relay Therapeutics, Inc. (RLAY): Investor Outlook On A Biotech With 33% Potential Upside - DirectorsTalk Interviews
Is Relay Therapeutics Inc (RLAY) Overvalued After Q2 Earnings Mi - GuruFocus
Guggenheim reiterates Buy on Relay Therapeutics stock, $26 target By Investing.com - Investing.com Canada
Relay Therapeutics president and CEO Sanjiv Patel sells $943,736 in stock - Investing.com Nigeria
Relay Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26.31, Implies 33% Upside - TradingView
Relay Therapeutics Q2 Results: Sales drop 48% YoY, miss estimates - scanx.trade
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings Flash (RLAY) Relay Therapeutics Posts Q2 Loss $0.41 per Share, vs. FactSet Est of $0.39 Loss - marketscreener.com
릴레이 테라퓨틱스 (RLAY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
릴레이 테라퓨틱스 주식 (RLAY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SVF Pauling (Cayman) Ltd | 10% Owner |
Aug 25 '26 |
Sale |
19.40 |
6,000,000 |
116,400,000 |
21,904,963 |
0.85%
1.52%
자본화:
|
볼륨(24시간):